DNA methyltransferase inhibition restores erythropoietin production in fibrotic murine kidneys

Journal of Clinical Investigation

Volumn 126, Issue 2, 2016, Pages 721-731

  Chang, Yu Ting ^a   Yang, Ching Chin ^a   Pan, Szu Yu ^a,b,c   Chou, Yu Hsiang ^a,b   Chang, Fan Chi ^a,b,d   Lai, Chun Fu ^b   Tsai, Ming Hsuan ^a   Hsu, Huan Lun ^b   Lin, Ching Hung ^b   Chiang, Wen Chih ^b   Wu, Ming Shiou ^b   Chu, Tzong Shinn ^b   Chen, Yung Ming ^b   Lin, Shuei Liong ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 TYPE 1 COLLAGEN; AZACITIDINE; COLLAGEN TYPE 1; DNA METHYLTRANSFERASE; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; COLLAGEN TYPE I, ALPHA 1 CHAIN; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME INHIBITION; KIDNEY FIBROSIS; MOLECULAR MECHANICS; MOUSE; MYOFIBROBLAST; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; FIBROSIS; GENETICS; METABOLISM; PATHOLOGY; RENAL INSUFFICIENCY, CHRONIC; TRANSGENIC MOUSE;

ANIMALS; AZACITIDINE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; COLLAGEN TYPE I; DNA MODIFICATION METHYLASES; ERYTHROPOIETIN; FIBROSIS; MICE; MICE, TRANSGENIC; MYOFIBROBLASTS; PERICYTES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RENAL INSUFFICIENCY, CHRONIC;

EID: 84956934760     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI82819     Document Type: Article

References (46)

1. Erslev AJ. Erythropoietin. N Engl J Med. 1991;324(19):1339-1344.
2. Eschbach JW. Erythropoietin 1991 - an overview. Am J Kidney Dis. 1991;18(4 suppl 1):3-9.
3. Brookhart MA, et al. The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol. 2008;19(7):1389-1395.
4. Walle AJ, Wong GY, Clemons GK, Garcia JF, Niedermayer W. Erythropoietin-hematocrit feedback circuit in the anemia of end-stage renal disease. Kidney Int. 1987;31(5):1205-1209.
5. Chandra M, Clemons GK, McVicar MI. Relation of serum erythropoietin levels to renal excretory function: evidence for lowered set point for erythropoietin production in chronic renal failure. J Pediatr. 1988;113(6):1015-1021.
6. Erslev AJ, Caro J, Kansu E, Silver R. Renal and extrarenal erythropoietin production in anaemic rats. Br J Haematol. 1980;45(1):65-72.
7. Bernhardt WM, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010;21(12):2151-2156.
8. Maxwell PH, et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int. 1993;44(5):1149-1162.
9. Bachmann S, Le Hir M, Eckardt KU. Co-localization of erythropoietin mRNA and ecto-5'-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem. 1993;41(3):335-341.
10. Obara N, Suzuki N, Kim K, Nagasawa T, Imagawa S, Yamamoto M. Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood. 2008;111(10):5223-5232.
11. Asada N, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest. 2011;121(10):3981-3990.
12. Bussolati B, Lauritano C, Moggio A, Collino F, Mazzone M, Camussi G. Renal CD133(+)/CD73(+) progenitors produce erythropoietin under hypoxia and prolyl hydroxylase inhibition. J Am Soc Nephrol. 2013;24(8):1234-1241.
13. Yamazaki S, et al. A mouse model of adult-onset anaemia due to erythropoietin deficiency. Nat Commun. 2013;4:1950.
14. Souma T, et al. Plasticity of renal erythropoietin-producing cells governs fibrosis. J Am Soc Nephrol. 2013;24(10):1599-1616.
15. Suzuki N, et al. Specific contribution of the erythropoietin gene 3' enhancer to hepatic erythropoiesis after late embryonic stages. Mol Cell Biol. 2011;31(18):3896-3905.
16. Storti F, et al. A novel distal upstream hypoxia response element regulating oxygen-dependent erythropoietin gene expression. Haematologica. 2014;99(4):e45-e48.
17. Yin H, Blanchard KL. DNA methylation represses the expression of the human erythropoietin gene by two different mechanisms. Blood. 2000;95(1):111-119.
18. Dewi FR, Fatchiyah F. Methylation impact analysis of erythropoietin (EPO) gene to hypoxia inducible factor-1alpha (HIF-1α) activity. Bioinformation. 2013;9(15):782-787.
19. Rossler J, et al. Hypoxia-induced erythropoietin expression in human neuroblastoma requires a methylation free HIF-1 binding site. J Cell Biochem. 2004;93(1):153-161.
20. Steinmann K, Richter AM, Dammann RH. Epigenetic silencing of erythropoietin in human cancers. Genes Cancer. 2011;2(1):65-73.
21. Duffield JS. Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest. 2014;124(6):2299-2306.
22. Lin SL, Kisseleva T, Brenner DA, Duffield JS. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol. 2008;173(6):1617-1627.
23. Humphreys BD, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol. 2010;176(1):85-97.
24. Lin SL, et al. Targeting endothelium-pericyte crosstalk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol. 2011;178(2):911-923.
25. Schrimpf C, et al. Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury. J Am Soc Nephrol. 2012;23(5):868-883.
26. Chang FC, Chou YH, Chen YT, Lin SL. Novel insights into pericyte-myofibroblast transition and therapeutic targets in renal fibrosis. J Formos Med Assoc. 2012;111(11):589-598.
27. Kramann R, et al. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell. 2015;16(1):51-66.
28. Chen YT, et al. Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int. 2011;80(11):1170-1181.
29. Wu CF, et al. Transforming growth factor beta-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis. Am J Pathol. 2013;182(1):118-131.
30. Ren S, et al. LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc Natl Acad Sci U S A. 2013;110(4):1440-1445.
31. Castano AP, et al. Serum amyloid P inhibits fibrosis through FcγR-dependent monocyte-macrophage regulation in vivo. Sci Transl Med. 2009;1(5):5ra13.
32. Bechtel W, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med. 2010;16(5):544-550.
33. Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal ablation of Hif-2α results in anemia. Proc Natl Acad Sci U S A. 2007;104(7):2301-2306.
34. Kapitsinou PP, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood. 2010;116(16):3039-3048.
35. Paliege A, et al. Hypoxia-inducible factor-2α-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int. 2010;77(4):312-318.
36. Tsai H-C, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21(3):430-446.
37. Shen H, Laird PW. In epigenetic therapy, less is more. Cell Stem Cell. 2012;10(4):353-354.
38. Issa J-PJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103(5):1635-1640.
39. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int. 1997;51(3):622-630.
40. Chiang CK, Tanaka T, Inagi R, Fujita T, Nangaku M. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest. 2011;91(11):1564-1571.
41. Radtke HW, Frei U, Erbes PM, Schoeppe W, Koch KM. Improving anemia by hemodialysis: effect of serum erythropoietin. Kidney Int. 1980;17(3):382-387.
42. Tanaka T, Nangaku M. The role of hypoxia, increased oxygen consumption, and hypoxia-inducible factor-1 α in progression of chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19(1):43-50.
43. Wang Z, et al. Hypoxia-inducible factor-1α contributes to the profibrotic action of angiotensin II in renal medullary interstitial cells. Kidney Int. 2011;79(3):300-310.
44. Pritchett TL, Bader HL, Henderson J, Hsu T. Conditional inactivation of the mouse von Hippel-Lindau tumor suppressor gene results in wide-spread hyperplastic, inflammatory and fibrotic lesions in the kidney. Oncogene. 2015;34(20):2631-2639.
45. Chen YT, et al. Lineage tracing reveals distinctive fates for mesothelial cells and submesothelial fibroblasts during peritoneal injury. J Am Soc Nephrol. 2014;25(12):2847-2858.
46. Tamura M, Aizawa R, Hori M, Ozaki H. Progressive renal dysfunction and macrophage infiltration in interstitial fibrosis in an adenine-induced tubulointerstitial nephritis mouse model. Histochem Cell Biol. 2009;131(4):483-490.